Company intelligence / Profile preview

BC3 Technologies

Baltimore, Maryland, USA

Ownership: Private
Employees: ~6
Development stage: Other

Overview

BC3 Technologies' FDA-cleared SEAL Hemostatic Wound Spray is the first aerosolized chitosan product for rapid hemorrhage control, with proven efficacy in EMS, battlefield, and civilian emergency settings. The device is commercially available in the US and internationally. Field validation in Maryland and international use (notably in Ukraine) shows rapid and effective bleeding cessation, accepted as protocol in Maryland EMS and deployed in multiple US and global agencies.

Therapeutic areas: CardiovascularHematologyOtherDermatology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

First Aid Only (Acme United Corporation)University of Maryland Shock TraumaMaryland Institute for Emergency Medical Services Systems (MIEMSS)Elite First Aid

Beyond the preview

Go deeper on BC3 Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC3 Technologies.

Explore the full profile